Previous 10 | Next 10 |
Cumberland Pharmaceuticals CPIX +90% on FDA label expansion for pain therapy Pioneer Power Solutions (NASDAQ:PPSI) +66%. First Wave BioPharma (NASDAQ:FWBI) +53% announces independent data monitoring committee provides positive interim safety assessment for part 2 COVID-19 RESER...
NEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it will commence preparation for clinical trials of its...
Start Time: 16:30 End Time: 16:53 GBS Inc. (GBS) Q1 2022 Earnings Conference Call November 11, 2021, 16:30 PM ET Company Participants Steven Boyages - CEO Spiro Sakiris - CFO Tim McCarthy - LifeSci Advisors, IR Conference Call Participants John Vandermosten - Zacks Presentation Operator Greet...
GBS (NASDAQ:GBS): FQ1 GAAP EPS of -$0.10. As of September 30, 2021, the Company’s cash, cash equivalents and marketable securities totaled approximately $12.6 million, compared to approximately $12.57 million on June 30, 2021. Shares +3.09%. Press Release For further details see: ...
– Announced Pre-Submission Package sent to the FDA for its Glucose Biosensor Test – – Clinical Validation Study Results for SARS CoV2 Ab Test – – Evaluating site locations for build out of high-tech manufacturing facility supp...
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the firs...
NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced changes to its executive leadership team as the Company adv...
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has filed a Pre-Submission package with the United State...
H.C. Wainwright 23 rd Global Investor Conference: September 13 th - 15 th Benzinga Healthcare Small Cap Conference: September 29 th - 30 th NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- GBS (Nasdaq: GBS), a life sciences c...
Gainers: ABVC BioPharma (NASDAQ:ABVC) +32%, Bellicum Pharmaceuticals (NASDAQ:BLCM) +22%, Evaxion Biotech (NASDAQ:EVAX) +22%, GBS (NASDAQ:GBS) +22%, PetVivo (NASDAQ:PETV) +17%. Losers: Avidity Biosciences (NASDAQ:RNA) -18%, So-Young (...
News, Short Squeeze, Breakout and More Instantly...
GBS Inc. Company Name:
GBS Stock Symbol:
NASDAQ Market:
The transaction further solidifies GBS’ leadership in non-invasive, real-time diagnostic testing with an expanded portfolio and geographical reach GBS’ global footprint includes operations in Australia, United Kingdom and the US NEW YORK, Oct. 04, 2022 (G...
- Entered into exclusive agreement with Intelligent Fingerprinting Ltd. (IFP) for screening technology focused on drugs of abuse towards a prospective acquisition - - Completed collection and analysis in a study with coincidental sampling of oral fluid and blood to evaluate the ...
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the four...